<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-442
Date of Submission: 2025-01-17

This report was submitted by a Pharmacist from Brown-Smith Medical Center concerning patient ANON-PX-9715. The subject is a 29-year-old female with a significant medical history including osteoarthritis, type 2 diabetes, hypertension, coronary artery disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Omeprazole administered via the Intravenous route at a dosage of 396mg, initiated on 2024-10-23 for Gastroesophageal reflux disease and discontinued on 2024-11-30.

On approximately 2024-11-28, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Angioedema, Anaphylaxis. The Angioedema was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Anaphylaxis was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed blood and advised necessary. The current patient status regarding this symptom is 'Fatal'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 10 was calculated, The assessment concluded the relationship was 'Highly Probable'. Dechallenge/Rechallenge status was noted as: 'Rechallenge not performed'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Talk mind success alone maybe cover street range. Rest most blood support physical manage. Sport eight start upon why at form job.</data>
report_id: ADR-2025-442
report_date: '2025-01-17'
patient_details:
  patient_id: ANON-PX-9715
  gender: Female
  relevant_history:
  - osteoarthritis
  - type 2 diabetes
  - hypertension
  - coronary artery disease
  age_at_reaction: 29
suspected_drugs:
- drug_name: Omeprazole
  dosage: 396mg
  route_of_administration: Intravenous
  start_date: '2024-10-23'
  indication_for_use: Gastroesophageal reflux disease
  end_date: '2024-11-30'
adverse_reactions:
- symptom_name: Angioedema
  onset_date: '2024-11-28'
  severity: Mild
  outcome: Fatal
  intervention_required: false
- symptom_name: Anaphylaxis
  onset_date: '2024-11-28'
  severity: Mild
  outcome: Fatal
  intervention_required: true
  intervention_details: Prescribed blood and advised necessary.
causality_assessment:
  assessment_conclusion: Highly Probable
  dechallenge_rechallenge: Rechallenge not performed
  naranjo_score: 10
reporting_facility: Brown-Smith Medical Center
reporter_type: Pharmacist
notes: Talk mind success alone maybe cover street range. Rest most blood support physical
  manage. Sport eight start upon why at form job.
